Glibenclamide/metformin

Glibenclamide/metformin
Combination of
Glyburide (Glibenclamide)	Sulfonylurea
Metformin	Biguanide
Clinical data
Trade names	Glucovance
Other names	glyburide/metformin
AHFS/Drugs.com	Professional Drug Facts
MedlinePlus	a699055
Pregnancy category	AU: C
Routes of administration	By mouth
ATC code	None
Legal status
Legal status	US: ℞-only
Identifiers
CAS Number	338752-31-1
KEGG	D10266

Glibenclamide/metformin, also known as glyburide/metformin and sold under the brand name Glucovance, is a fixed-dose combination anti-diabetic medication used to treat type 2 diabetes. It contains glibenclamide, a sulfonylureas, and metformin, a biguanide.^[1]

References

↑ "Glyburide and metformin hydrochloride tablet". DailyMed. 10 June 2020. Retrieved 11 August 2020.

External links

"Glyburide mixture with Metformin hydrochloride". Drug Information Portal. U.S. National Library of Medicine.

Oral diabetes medication, insulins and insulin analogs, and other drugs used in diabetes (A10)

Insulins/insulin analogs

fast-acting	Insulin aspart Insulin glulisine Insulin lispro
short-acting	Regular insulin
long-acting	Insulin detemir^# Insulin glargine^# (+lixisenatide) NPH insulin Lente insulin^‡ Ultralente insulin^‡
ultra-long-acting	Insulin degludec (+insulin aspart, +liraglutide)
inhalable	Exubera^‡ Afrezza

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Non-insulins

Insulin sensitizers

Biguanides	Buformin^‡ Metformin^# Phenformin^‡
TZDs/"glitazones" (PPAR)	Ciglitazone^§ Darglitazone^§ Englitazone^§ Lobeglitazone Netoglitazone^§ Pioglitazone Rivoglitazone^† Rosiglitazone Troglitazone^‡
Dual PPAR agonists	Aleglitazar^† Muraglitazar^§ Saroglitazar Tesaglitazar^§

K⁺_ATP

Sulfonylureas	1st generation: Acetohexamide Carbutamide Chlorpropamide Glycyclamide Metahexamide Tolazamide Tolbutamide 2nd generation: Glibenclamide (glyburide) Glibornuride Glicaramide Gliclazide^# Glimepiride Glipizide Gliquidone Glisoxepide Glyclopyramide
Meglitinides/"glinides"	Mitiglinide Nateglinide Repaglinide

GLP-1/GIP receptor agonists

DPP-4 inhibitors/"gliptins"

FFAR1 agonists

Fasiglifam^†

Other

Aldose reductase inhibitors	Epalrestat Fidarestat^§ Ranirestat^† Tolrestat^‡ Zenarestat^§
Alpha-glucosidase inhibitors	Acarbose Miglitol Voglibose
Amylin analog	Pramlintide
SGLT2 inhibitors/"gliflozins"	Canagliflozin Dapagliflozin Empagliflozin^# Ertugliflozin Ipragliflozin Luseogliflozin Remogliflozin^§ Sergliflozin^§ Tofogliflozin^†
Other	Benfluorex^‡ Bromocriptine Imeglimin

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.